MAPT and Alzheimer disease: In vivo quantification of Aß and Tau proteins and their ratio in the cerebrospinal fluid (CSF), coupled with neuroimaging and neuropsychological studies, is often used to evaluate the likelihood of probable or possible AD diagnosis [4].